Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 13/20 | 0.71 |
| ▸ | STK3 | Q13188 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129771 | 1.00 | STK4 (0.71) | STK4STK3EGFRERBB2 | |
| SCHEMBL5255823 | 0.96 | STK4 (0.65) | STK4STK3EGFRERBB2 | |
| SCHEMBL13915763 | 0.89 | STK4 (0.59) | STK4STK3EGFRERBB2 | |
| SCHEMBL2131485 | 0.88 | STK4 (0.57) | STK4STK3EGFRERBB2 | |
| SCHEMBL30847382 | 0.88 | STK4 (0.68) | STK4STK3EGFRERBB2 | |
| SCHEMBL2543431 | 0.88 | STK4 (0.68) | STK4STK3EGFRERBB2 | |
| SCHEMBL14048142 | 0.88 | STK4 (0.70) | STK4STK3EGFRERBB2 | |
| SCHEMBL5261113 | 0.84 | STK4 (0.55) | STK4EGFRERBB2 | |
| SCHEMBL29515043 | 0.83 | STK4 (1.00) | STK4STK3EGFRERBB2 | |
| SCHEMBL22419865 | 0.83 | STK4 (1.00) | STK4STK3EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679473-B | Lenatinib intermediate crystal, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-111875539-B | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 苏中药业集团股份有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-114605321-A | Impurities of substituted butene amide raw material and preparation product and analysis method thereof | 苏中药业集团股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-112679473-B | Lenatinib intermediate crystal, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-116135844-A | Heterocyclic compound and preparation method and application thereof | 苏中药业集团股份有限公司 | 2023-05-19 | — | — | CN | disclosed |
| CN-112759583-B | Quinoline derivative containing furyl and preparation method and application thereof | 河南省医药科学研究院 | 2022-10-11 | — | — | CN | disclosed |
| CN-112694439-B | Phenyl acrylamide quinoline derivative and preparation method and application thereof | 河南省医药科学研究院 | 2022-08-30 | — | — | CN | disclosed |
| CN-111875539-B | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 苏中药业集团股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-111875539-B | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 苏中药业集团股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114605321-A | Impurities of substituted butene amide raw material and preparation product and analysis method thereof | 苏中药业集团股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-112625025-B | Pyridyl substituted quinoline derivative and its prepn and use | 河南省医药科学研究院 | 2022-03-29 | — | — | CN | disclosed |